SOPHiA GENETICS (NASDAQ:SOPH) Sees Strong Trading Volume – Should You Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH) saw unusually-high trading volume on Tuesday . Approximately 1,310,764 shares were traded during trading, an increase of 396% from the previous session’s volume of 264,333 shares.The stock last traded at $7.9040 and had previously closed at $7.86.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. BTIG Research increased their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright lifted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Trading Up 0.4%

The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The company has a fifty day moving average of $7.08 and a 200-day moving average of $5.71. The firm has a market capitalization of $662.35 million, a PE ratio of -6.88 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $5.80, for a total value of $290,400.20. Following the transaction, the chief executive officer owned 3,601,493 shares in the company, valued at approximately $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the transaction, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. The trade was a 2.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 357,260 shares of company stock worth $2,317,759 in the last 90 days. 4.88% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of the business. Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at about $866,000. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $9,809,000. Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the 1st quarter worth approximately $1,772,000. 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS during the fourth quarter worth approximately $973,000. Finally, Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter worth approximately $2,009,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.